Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTGNASDAQ:COLLNASDAQ:MLYSNYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTGBCTG Acquisition$10.68$9.83▼$14.00$218.05MN/A36,697 shs2,024 shsCOLLCollegium Pharmaceutical$30.30+2.5%$28.98$23.23▼$42.29$950.14M0.64398,219 shs267,653 shsMLYSMineralys Therapeutics$13.70+1.3%$14.90$8.24▼$18.38$881.82M-0.29543,347 shs717,345 shsRCUSArcus Biosciences$8.35+2.6%$8.82$6.50▼$18.98$861.91M0.8879,467 shs1.09 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTGBCTG Acquisition0.00%0.00%0.00%0.00%0.00%COLLCollegium Pharmaceutical+2.47%+0.63%+3.10%+1.00%-7.11%MLYSMineralys Therapeutics+1.26%-3.11%-12.91%-2.14%+12.57%RCUSArcus Biosciences+2.20%-4.73%-7.02%+5.83%-45.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTGBCTG AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACOLLCollegium Pharmaceutical4.0149 of 5 stars3.41.00.03.01.60.82.5MLYSMineralys Therapeutics2.1316 of 5 stars3.41.00.00.01.54.20.0RCUSArcus Biosciences2.8227 of 5 stars4.43.00.00.01.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTGBCTG Acquisition 0.00N/AN/AN/ACOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7544.39% UpsideMLYSMineralys Therapeutics 2.75Moderate Buy$32.25135.40% UpsideRCUSArcus Biosciences 2.89Moderate Buy$21.29154.92% UpsideCurrent Analyst Ratings BreakdownLatest BCTG, COLL, MLYS, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.006/10/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$15.005/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.005/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.005/9/2025RCUSArcus BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.005/8/2025RCUSArcus BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/7/2025RCUSArcus BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.005/7/2025RCUSArcus BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $26.004/23/2025RCUSArcus BiosciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $14.004/9/2025COLLCollegium PharmaceuticalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTGBCTG AcquisitionN/AN/AN/AN/A$0.23 per shareN/ACOLLCollegium Pharmaceutical$631.45M1.54$12.63 per share2.40$7.10 per share4.27MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ARCUSArcus Biosciences$258M3.43N/AN/A$5.30 per share1.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTGBCTG Acquisition-$120KN/A0.00N/AN/AN/AN/AN/AN/ACOLLCollegium Pharmaceutical$69.19M$1.2224.845.03N/A6.61%99.08%15.14%8/6/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-71.15%-65.71%8/12/2025 (Estimated)RCUSArcus Biosciences-$283M-$4.19N/AN/AN/A-258.94%-70.58%-32.97%8/4/2025 (Estimated)Latest BCTG, COLL, MLYS, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/6/2025Q1 2025RCUSArcus Biosciences-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTGBCTG AcquisitionN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTGBCTG AcquisitionN/A4.804.80COLLCollegium Pharmaceutical3.301.081.01MLYSMineralys TherapeuticsN/A26.4826.48RCUSArcus Biosciences0.095.375.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTGBCTG Acquisition62.44%COLLCollegium PharmaceuticalN/AMLYSMineralys Therapeutics84.46%RCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipBCTGBCTG AcquisitionN/ACOLLCollegium Pharmaceutical2.51%MLYSMineralys Therapeutics33.24%RCUSArcus Biosciences9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTGBCTG AcquisitionN/A21.38 millionN/ANot OptionableCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableMLYSMineralys Therapeutics2865.18 million43.51 millionOptionableRCUSArcus Biosciences500105.89 million95.72 millionOptionableBCTG, COLL, MLYS, and RCUS HeadlinesRecent News About These CompaniesArcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer TreatmentJuly 1 at 4:07 AM | msn.comArcus Biosciences (NYSE:RCUS) Trading Down 6.3% - Here's What HappenedJune 27, 2025 | marketbeat.comIncyte, FDA, Sun Pharma and more—Chutes & LaddersJune 27, 2025 | fiercebiotech.comFArcus Biosciences Announces New Employment Inducement Grants - Business WireJune 26, 2025 | businesswire.comPrecision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’June 26, 2025 | msn.comBrokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Target Price at $24.13June 26, 2025 | americanbankingnews.comPrecision BioSciences Shares Surge Following FDA Rare Pediatric Disease DesignationJune 25, 2025 | msn.comPrecision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%June 25, 2025 | msn.comArcus Biosciences, Inc. (RCUS) Cash Flow - Yahoo FinanceJune 24, 2025 | finance.yahoo.comRCUS Arcus Biosciences, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comArcus Biosciences Announces New Employment Inducement GrantsJune 24, 2025 | businesswire.comArcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Moderate Buy" by AnalystsJune 23, 2025 | marketbeat.comThe trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gambleJune 13, 2025 | fiercebiotech.comFArcus Biosciences (NYSE:RCUS) Shares Down 3.8% - What's Next?June 11, 2025 | marketbeat.comStock Traders Purchase Large Volume of Call Options on Arcus Biosciences (NYSE:RCUS)June 11, 2025 | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsJune 10, 2025 | businesswire.comResearch Analysts Offer Predictions for RCUS FY2026 EarningsJune 10, 2025 | marketbeat.comH.C. Wainwright maintains Buy rating for Arcus Biosciences stockJune 4, 2025 | investing.comArcus Biosciences, Inc. (NYSE:RCUS) Short Interest Up 25.2% in MayJune 4, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Trading 10.6% Higher - Here's What HappenedJune 4, 2025 | marketbeat.comNuveen Asset Management LLC Has $1.96 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS)June 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeTesla Bulls and Bears Collide: What Investors Should KnowBy Sam Quirke | June 18, 2025View Tesla Bulls and Bears Collide: What Investors Should KnowBCTG, COLL, MLYS, and RCUS Company DescriptionsBCTG Acquisition NASDAQ:BCTGBCTG Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses primarily located in North America and Europe in the biotechnology industry. The company was incorporated in 2020 and is based in San Diego, California.Collegium Pharmaceutical NASDAQ:COLL$30.30 +0.73 (+2.47%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$30.30 0.00 (-0.02%) As of 07/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Mineralys Therapeutics NASDAQ:MLYS$13.70 +0.17 (+1.26%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$13.45 -0.25 (-1.82%) As of 07/1/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Arcus Biosciences NYSE:RCUS$8.35 +0.21 (+2.58%) Closing price 07/1/2025 03:59 PM EasternExtended Trading$8.34 -0.01 (-0.12%) As of 07/1/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
